Erratum: Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma (Cancer DOI: 10.1002/cncr.28521);Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma

Cancer

Volumn 120, Issue 7, 2014, Pages 1059-1067

  Joseph, Richard W ^a   Kapur, Payal ^b   Serie, Daniel J ^a   Eckel Passow, Jeanette E ^c   Parasramka, Mansi ^a   Ho, Thai ^d   Cheville, John C ^d   Frenkel, Eugene ^e   Rakheja, Dinesh ^b   Brugarolas, James ^e,f   Parker, Alexander ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

BAP1; carcinoma; kidney neoplasms; renal cell; survival; tumor biomarkers

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; KI 67 ANTIGEN; SURVIVIN;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEPHRON SPARING SURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

BAP1; CARCINOMA; KIDNEY NEOPLASMS; RENAL CELL; SURVIVAL; TUMOR BIOMARKERS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84899421896     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28615     Document Type: Erratum

References (22)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Brugarolas J,. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 2013; 19: 324-332.
3. Hakimi AA, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013; 19: 3259-3267.
4. Kapur P, Pena-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013; 14: 159-167.
5. Creighton CJ, Morgan M, Gunaratne PH, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013.
6. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7: 85-90.
7. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994; 91: 9700-9704.
8. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012; 44: 751-759.
9. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011; 469: 539-542.
10. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010; 463: 360-363.
11. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013; 92: 974-980.
12. Farley MN, Schmidt LS, Mester JL, et al. Germline BAP1 mutation predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res. 2013; 11: 1061-1071.
13. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G,. BAP1 and cancer. Nat Rev Cancer. 2013; 13: 153-159.
14. Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010; 57: 102-109.
15. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H,. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002; 168: 2395-2400.
16. Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W,. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol. 2007; 8: 554-558.
17. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001; 19: 1649-1657.
18. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P,. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001; 166: 63-67.
19. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005; 173: 48-51.
20. Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009; 115: 2092-2103.
21. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387.
22. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-892.